Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-12-11
DOI
10.3389/fonc.2019.01400
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear cell Renal Cell Cancer - Data from a Randomized Phase III Trial
- (2019) A. Ari Hakimi et al. Cancer Discovery
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma
- (2019) Marie Auvray et al. EUROPEAN JOURNAL OF CANCER
- Clear-cell renal cell carcinoma: molecular characterization of IMDC risk groups and sarcomatoid tumors
- (2019) Annelies Verbiest et al. Clinical Genitourinary Cancer
- Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial
- (2019) Sergio Bracarda et al. Clinical Genitourinary Cancer
- Alternative Splicing in Angiogenesis
- (2019) Elizabeth Bowler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
- (2019) A.Y. Shah et al. EUROPEAN JOURNAL OF CANCER
- Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
- (2019) Huan Deng et al. Frontiers in Oncology
- First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium
- (2019) Shaan Dudani et al. EUROPEAN UROLOGY
- Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting
- (2018) Annelies Verbiest et al. Clinical Genitourinary Cancer
- Current and Emerging Treatments for Metastatic Renal Cell Carcinoma
- (2018) Carla Cavaliere et al. CURRENT CANCER DRUG TARGETS
- Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy
- (2018) Annelies Verbiest et al. EUROPEAN UROLOGY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Response to Pazopanib in an Elderly Man with mRCC. A Case Report
- (2018) Carmine D'Aniello et al. TUMORI
- Genomics and clinical correlates of renal cell carcinoma
- (2018) Thomas J. Mitchell et al. WORLD JOURNAL OF UROLOGY
- The Identification of Immunological Biomarkers in Kidney Cancers
- (2018) Antonio Lopez-Beltran et al. Frontiers in Oncology
- Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness
- (2017) Daniel J. Serie et al. EUROPEAN UROLOGY
- CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
- (2017) Bernard Escudier et al. EUROPEAN UROLOGY
- Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model
- (2017) Guillermo de Velasco et al. ONCOLOGIST
- Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma
- (2017) María Apellániz-Ruiz et al. Pharmacogenetics and Genomics
- Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC)
- (2017) P. Wolter et al. JOURNAL OF CLINICAL ONCOLOGY
- A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study.
- (2017) D. Y. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of CXCR4 expression to predict the efficacy of sorafenib treatment in patients with metastatic renal cell carcinoma.
- (2017) J. Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of hand-foot syndrome (HFS) as a potential biomarker of sunitinib (SU) efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST).
- (2017) I. Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma
- (2016) R. Nadal et al. ANNALS OF ONCOLOGY
- First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study
- (2016) M. Bersanelli et al. ANNALS OF ONCOLOGY
- An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
- (2016) A. Ari Hakimi et al. CANCER CELL
- The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review
- (2016) Giuseppe Di Lorenzo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients
- (2016) Xiaoyan Liu et al. Oncotarget
- Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma
- (2016) Fengju Chen et al. Cell Reports
- Corrigendum: Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”
- (2016) Sabrina C. Cecere et al. Frontiers in Pharmacology
- Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian “Real-World” SAX Study
- (2016) Carmine D'Aniello et al. Frontiers in Pharmacology
- Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”
- (2016) Sabrina C. Cecere et al. Frontiers in Pharmacology
- Low Expression of miR-126 Is a Prognostic Marker for Metastatic Clear Cell Renal Cell Carcinoma
- (2015) Heba W.Z. Khella et al. AMERICAN JOURNAL OF PATHOLOGY
- Structure–fluctuation–function relationships of seven pro-angiogenic isoforms of VEGFA, important mediators of tumorigenesis
- (2015) Francesca Bergantino et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
- (2015) C-F Xu et al. BRITISH JOURNAL OF CANCER
- Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
- (2015) B. Beuselinck et al. CLINICAL CANCER RESEARCH
- Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma
- (2015) Bernard Escudier et al. Clinical Genitourinary Cancer
- Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis
- (2015) Andreas Nearchou et al. Clinical Genitourinary Cancer
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma
- (2015) Sara Samaan et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular and immunologic markers of kidney cancer—potential applications in predictive, preventive and personalized medicine
- (2015) Amanda Mickley et al. EPMA Journal
- Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma
- (2014) R. Elaidi et al. ANNALS OF ONCOLOGY
- PD-L1 expression in nonclear-cell renal cell carcinoma
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- mTOR signaling in tumorigenesis
- (2014) Kai Xu et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
- (2014) B Escudier et al. BRITISH JOURNAL OF CANCER
- Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
- (2014) Robert J. Motzer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Identification of a Variant in KDR Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib
- (2014) M. L. Maitland et al. CLINICAL CANCER RESEARCH
- Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma
- (2014) Anna Kornakiewicz et al. Current Signal Transduction Therapy
- ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma
- (2014) Samira A. Brooks et al. EUROPEAN UROLOGY
- Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
- (2014) Marco Gerlinger et al. NATURE GENETICS
- MicroRNAs and their applications in kidney diseases
- (2014) Shawn S. Badal et al. PEDIATRIC NEPHROLOGY
- Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma
- (2014) Celia Prior et al. PLoS One
- miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis
- (2013) R I McCormick et al. BRITISH JOURNAL OF CANCER
- MicroRNA expression signatures of stage, grade, and progression in clear cell RCC
- (2013) Banumathy Gowrishankar et al. CANCER BIOLOGY & THERAPY
- Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
- (2013) M. J. Brauer et al. CLINICAL CANCER RESEARCH
- The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma
- (2013) T. K. Choueiri et al. CLINICAL CANCER RESEARCH
- Optimal Management of Metastatic Renal Cell Carcinoma: Current Status
- (2013) Bernard Escudier et al. DRUGS
- Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort
- (2013) Roberto Iacovelli et al. EUROPEAN JOURNAL OF CANCER
- A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
- (2013) Cora N. Sternberg et al. EUROPEAN JOURNAL OF CANCER
- Clinical and pathological impact ofVHL, PBRM1, BAP1, SETD2, KDM6A, andJARID1cin clear cell renal cell carcinoma
- (2013) Lucy Gossage et al. GENES CHROMOSOMES & CANCER
- Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation
- (2013) Payal Kapur et al. LANCET ONCOLOGY
- The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients
- (2013) Mhd Y. Al-Marrawi et al. Targeted Oncology
- Predictors of Response to Targeted Therapy in Renal Cell Carcinoma
- (2012) Laurie J. Eisengart et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma
- (2012) Roberto Iacovelli et al. BJU INTERNATIONAL
- Renal cancer biomarkers: the promise of personalized care
- (2012) Naveen S Vasudev et al. BMC Medicine
- High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer
- (2012) C. D'Alterio et al. CURRENT CANCER DRUG TARGETS
- Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma
- (2012) Christoph Seidel et al. EUROPEAN JOURNAL OF CANCER
- Predictive factors for response to treatment in patients with advanced renal cell carcinoma
- (2012) Carolina Muriel López et al. INVESTIGATIONAL NEW DRUGS
- A Possible Role for MicroRNA-141 Down-Regulation in Sunitinib Resistant Metastatic Clear Cell Renal Cell Carcinoma Through Induction of Epithelial-to-Mesenchymal Transition and Hypoxia Resistance
- (2012) Joost Berkers et al. JOURNAL OF UROLOGY
- Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
- (2012) Hai T Tran et al. LANCET ONCOLOGY
- BAP1 loss defines a new class of renal cell carcinoma
- (2012) Samuel Peña-Llopis et al. NATURE GENETICS
- Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?
- (2011) R. Sabatier et al. ANNALS OF ONCOLOGY
- Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib
- (2011) Jenny J. Kim et al. CANCER
- Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
- (2011) Judith Manola et al. CLINICAL CANCER RESEARCH
- 1139 POSTER Asthenia and Fatigue as Potential Biomarkers of Sunitinib Efficacy in Metastatic Renal Cell Carcinoma
- (2011) M.P. Davis et al. EUROPEAN JOURNAL OF CANCER
- 7103 ORAL Association of Single Nucleotide Polymorphisms (SNPs) in VEGF Pathway Genes With Progression-free Survival (PFS) and Blood Pressure (BP) in Metastatic Renal Cell Carcinoma (mRCC) in the Phase 3 Trial of Axitinib Versus Sorafenib (AXIS Trial)
- (2011) B. Escudier et al. EUROPEAN JOURNAL OF CANCER
- 7154 POSTER Hypothyroidism and Macrocytosis as Surrogate Markers for Response and Survival in Patients With Advanced Renal Cell Carcinoma Treated With Sunitinib as First-line Therapy
- (2011) A. Pinto et al. EUROPEAN JOURNAL OF CANCER
- Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
- (2011) E. Calvo et al. EUROPEAN JOURNAL OF CANCER
- Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
- (2011) Maxine Sun et al. EUROPEAN UROLOGY
- Meta-analysis of Clear Cell Renal Cell Carcinoma Gene Expression Defines a Variant Subgroup and Identifies Gender Influences on Tumor Biology
- (2011) A. Rose Brannon et al. EUROPEAN UROLOGY
- A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23
- (2011) Xifeng Wu et al. HUMAN MOLECULAR GENETICS
- Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
- (2011) Chun-Fang Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
- (2011) Jesus Garcia-Donas et al. LANCET ONCOLOGY
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
- (2011) Ignacio Varela et al. NATURE
- Molecular Sub-Classification of Renal Epithelial Tumors Using Meta-Analysis of Gene Expression Microarrays
- (2011) Thomas Sanford et al. PLoS One
- Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
- (2010) Toni K. Choueiri et al. BJU INTERNATIONAL
- The VHL-dependent regulation of microRNAs in renal cancer
- (2010) Calida S Neal et al. BMC Medicine
- Hypothyroidism in patients with renal cell carcinoma
- (2010) Manuela Schmidinger et al. CANCER
- The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib
- (2010) Naveen S. Basappa et al. CANCER
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2010) C. Pena et al. CLINICAL CANCER RESEARCH
- Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
- (2010) A. A. M. van der Veldt et al. CLINICAL CANCER RESEARCH
- Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma
- (2010) Giuseppe Di Lorenzo et al. EUROPEAN UROLOGY
- Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma
- (2010) Y. Tomita et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
- (2010) Gillian L. Dalgliesh et al. NATURE
- Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3
- (2010) Mark P Purdue et al. NATURE GENETICS
- Fatigue in Renal Cell Carcinoma: The Hidden Burden of Current Targeted Therapies
- (2010) J. M. G. Larkin et al. ONCOLOGIST
- Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
- (2009) P. Bono et al. ANNALS OF ONCOLOGY
- New treatment approaches in renal cell carcinoma
- (2009) Gaetano Facchini et al. ANTI-CANCER DRUGS
- Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma
- (2009) A. C. Young et al. CLINICAL CANCER RESEARCH
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypoxia inducible factor-1α correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma
- (2009) Gordana Đorđević et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
- (2009) Martin E Gore et al. LANCET ONCOLOGY
- Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth
- (2009) Romulo J C Albuquerque et al. NATURE MEDICINE
- Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
- (2008) M. E. Lacouture et al. ANNALS OF ONCOLOGY
- VEGF receptor protein–tyrosine kinases: Structure and regulation
- (2008) Robert Roskoski BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors
- (2008) M. L. Nickerson et al. CLINICAL CANCER RESEARCH
- Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
- (2008) Mathis Grossmann et al. CLINICAL ENDOCRINOLOGY
- Nur77 upregulates HIF-α by inhibiting pVHL-mediated degradation
- (2008) Bu-Yeon Kim et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma
- (2008) Toni K. Choueiri et al. JOURNAL OF UROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started